Top Penny Stocks For Your List Right Now
Penny stocks are some of the highest risk investments you can make. But their innate ability to record explosive gains is undeniable. What are penny stocks? All we’re talking about here are stocks under $5. According to the Securities & Exchange Commission, this is the formal definition of penny stocks.
As a result, even a 50 cent move can mean big gains for traders. One of the hardest things to master is consistent profitability without blowing up your trading account. Why would I say this? With so much attention on Reddit penny stocks, hype and emotions are coming first instead of fundamental research and technical analysis. This is where terms like “YOLO,” “HODL,” and “Diamond Hands” become the norm. All of these reference is the process of buying and holding at different levels of portfolio allocation.
I, for one, am not against using social media to get a temperature on sentiment. However, using that as your sole reason for buying or selling stocks can get you in trouble if you don’t know how to trade in the first place. Earlier today, we put out an article, “Reddit Penny Stocks & The Risks Of Social Media Trading In 2021.” In it, we explained the dangers and overal risk of just using social media to find the best penny stocks to buy.
The hype factor plays a key role in many breakout stock picks. But once the hype dies down, fundamentals and technicals are usually relied upon more. This is where the true test comes in. Do fundamentals and technicals stand up against the massive hype that has preceded a big rally? In most cases, there’s a decent-sized pullback, and that’s what we saw in a recently hyped Reddit penny stock, EEENF. The details are in the article referenced above. Needless to say, it’s important to understand the basics of how to day trade in these cases. It can help avoid significant losses at the very least.
Top Penny Stocks Today
With that point addressed, what are some of the top penny stocks today? You can look at broader sectors, or you can look at specific companies. The market as a whole is trading around all-time highs today, which has helped give a boost to many stocks. Regardless of this, whether the broader trend is up or down, there are usually plenty of penny stocks to watch.
- GT Biopharma Inc. (NASDAQ: GTBP)
- Odonate Therapeutics (NASDAQ: ODT)
- Fortress Biotech Inc. (NASDAQ: FBIO)
- Zosano Pharma Corp. (NASDAQ: ZSAN)
- Galectin Therapeutics Inc. (NASDAQ: GALT)
1. GT Biopharma Inc. (NASDAQ: GTBP)
At this point, GT Biopharma is a former penny stock to watch. But it has been one of the top names on our list discussed over the last few months. We’ve watched the company uplist from the OTC to the NASDAQ. We’ve also seen key milestones reached over the last few months.
The company’s main focus is advancing its immune therapy pipeline and treatment platform. GT’s tri-specific natural killer engagers (TriKE™) combines proteins that bridge an immune cell and a tumor cell then drive tumor cell killing power to exponential levels. It has led to new first-in-human phase studies to treat acute myeloid leukemia (AML).
Last month, the company released interim clinical trial results at the Innate Killer Summit. These were results from its current trial on the lead candidate, GTB-3550, in myelodysplastic syndromes and refractory/relapsed AML. Highlights from the update included up to 63.7% Reduction in Bone Marrow Blast Levels, restored endogenous NK cell function, proliferation, & immune surveillance in patients, and, importantly, no cytokine release syndrome observed.
The cytokine release syndrome is a systemic response to the activation and proliferation of CAR-T cells, which can provoke high fever and severe flu-like symptoms. It’s something that has been observed in current, commercialized treatment regimens & presents a unique opportunity for companies like GT Biopharma, which have effective treatments without extreme side effects.
Thanks to strong progress in its treatment pipeline, analysts have also begun following the company. Roth Capital recently started GT Biopharma with a Buy rating and announced a $25 price target.
2. Odonate Therapeutics (NASDAQ: ODT)
On the complete opposite end of the spectrum, Odonate was not a penny stock a few months ago but has now become one recently. In fact, the lowest price ODT stock traded at over the last 52 months was $12.56. How did Odonate end up as a penny stock?
As with many biotech companies, trials and treatment data are vital. Good data usually results in a favorable response in the market. But negative results can do the opposite. In Odonate’s case, the company announced it would wind down the company’s operations after discontinuing the development of its tesetaxel platform for breast cancer treatment. Odonate explained that clinical data for tesetaxel was “unlikely to secure approval” from the FDA.
Read More
- 4 Hot Penny Stocks To Watch This Week After Strong Jobs Report
- Top Penny Stocks To Watch For The Reopening Trade In 2021
The company said it plans to take a $14 million restructuring charge with the termination of its tesetaxel drug development. Odonate also expects to finish up the restructuring exercise by the end of June, according to its regulatory filing last month. Nevertheless, ODT stock has slowly climbed since the massive drop last month. In fact, over the last few weeks, shares have bounced from lows of $3.02 to highs this week of $3.65. But will there be a future for ODT stock, or is this the end of the line?
3. Fortress Biotech Inc. (NASDAQ: FBIO)
Though volume a lighter than other names on this list, Fortress Biotech is having a banner year in 2021. Shares of FBIO stock have climbed from $3.21 on January 4th to highs this week of $4.33. Within that timeframe, the penny stock also reached highs of $5.08.
Similar to GTBP mentioned above, analysts have also gotten behind the biotech company. This week, B. Riley boosted its price target to $98 from $8 after “strong Q4 2020 results” and kept its Buy rating. Fortress reported an EPS loss of $).65, which was much better than the $0.73 loss per share the previous year. Sales were also up significantly at $45.6 million compared to $36.6 million the year prior.
“As we look ahead to 2021, Fortress expects to deliver further top-line growth through a diversified, long-term revenue stream, and we and our partner companies anticipate multiple key value-creating milestones throughout the year. We have four product candidates in five ongoing pivotal clinical trials, with multiple other earlier-stage clinical trials progressing as well. Additionally, we intend to continue to in-license promising drugs and drug candidates, and to seek partners for late-stage programs to maximize each opportunity to its full potential.”
Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer
Fortress has helped build myriad biotech companies, including Mustang Bio, Caelum Biosciences, Checkpoint Therapeutics, and others. With a diversified portfolio and upcoming milestones, FBIO could be one of the penny stocks to watch right now.
4. Zosano Pharma Corp. (NASDAQ: ZSAN)
Shares of Zosano Pharma continue steadily climbing this week thanks to bullish sentiment in the broader biotechnology space. The company specializes in a transdermal microneedle system technology for drug delivery.
Like Fortress, Zosano also posted strong financial results for its Q4 and 2020 year. Earnings per share came in at a loss of 8 cents compared to a loss of 46 cents in the same period in 2019. One of the key highlights in its business update, Zosano pointed out that it completed a Type A meeting with the U.S. FDA Division of Neurology II regarding the requirements for resubmission of the Qtrypta (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application.
The company also partnered with EVERSANA to commercialize and distribute Qtrypta(TM), if approved, in the United States. EVERSANA provides commercial services to the life science industry.
“We expect to receive the FDA’s feedback on our pharmacokinetic study protocol shortly, and if supportive of our proposal, we are prepared to initiate this study quickly. Our clear priority is to resubmit our NDA as soon as possible so that patients suffering from debilitating migraines have access to Qtrypta, if approved.”
Steven Lo, President and CEO of Zosano
Following these results, analysts at Maxim Group raised their price target from m$1.50 to $2.50. The firm currently maintains a Buy on the stock.
5. Galectin Therapeutics Inc. (NASDAQ: GALT)
A typically quiet biotech penny stock, Galectin Therapeutics woke up in a big way on April 6th. This came after the company announced the launch of NAVIGATEnash.com. This trial website was designed to educate patients and physicians about liver cirrhosis resulting from non-alcoholic steatohepatitis (NASH). The site is also designed to support NAVIGATE, Galectin’s adaptive Phase 2b/3 study in NASH cirrhosis.
[Read More] Hot Penny To Buy According To Analysts With Price Targets Up To 195%
The NAVIGATE study now offers patients an opportunity to contribute to developing the first potential therapy targeting NASH cirrhosis. The aim is to improve clinical outcomes using information contributed to the platform.
Another catalyst this week was the insider trading activities in GALT stock. Director Kevin Freeman reported the purchase of 5,000 shares at an average price of $2.04 per share. Obviously, insider buying is a bullish sign to traders and, in this case, has helped support a bullish trend in the stock market today.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
